TY - JOUR
T1 - Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer
AU - Voelter, Verena
AU - Schuhmacher, Christoph
AU - Busch, Raymonde
AU - Peschel, Christian
AU - Rüdiger Siewert, Jörg
AU - Lordick, Florian
PY - 2004/9
Y1 - 2004/9
N2 - Background There is rising evidence that anemia and blood transfusion increase perioperative mortality in cancer patients. Patients who are treated with neoadjuvant chemotherapy with a curative intent are exposed to toxicity that may negatively affect their future outcome. Methods The charts of 29 patients (21 males; median age, 59.5 years; range, 37 to 73), receiving neoadjuvant chemotherapy for cT3 esophagogastric adenocarcinoma operated at a single university center in the year 2002, were retrospectively reviewed to assess the incidence of anemia and blood transfusions. Results Twenty-six patients received platinum-based chemotherapy over a period of 12 weeks and three patients more than 6 weeks. The median hemoglobin level (Hb level) before chemotherapy was 14.0 g/dL (range, 10.4 to 15.9 g/dL), the median decline of the Hb level was 2.9 g/dL (range, 0.3 to 6.3 g/dL); this drop was statistically significant (p < 0.001, 95% confidence interval). Patients who received preoperative blood transfusions (n = 8, 28%) had a significantly increased risk of developing postoperative complications (p = 0.028). Conclusions Preoperative chemotherapy for locally advanced esophagogastric cancer induces anemia and therefore leads to preoperative blood supplementation in a considerable number of patients. Data indicate that this may counteract the beneficial effects of neoadjuvant treatment.
AB - Background There is rising evidence that anemia and blood transfusion increase perioperative mortality in cancer patients. Patients who are treated with neoadjuvant chemotherapy with a curative intent are exposed to toxicity that may negatively affect their future outcome. Methods The charts of 29 patients (21 males; median age, 59.5 years; range, 37 to 73), receiving neoadjuvant chemotherapy for cT3 esophagogastric adenocarcinoma operated at a single university center in the year 2002, were retrospectively reviewed to assess the incidence of anemia and blood transfusions. Results Twenty-six patients received platinum-based chemotherapy over a period of 12 weeks and three patients more than 6 weeks. The median hemoglobin level (Hb level) before chemotherapy was 14.0 g/dL (range, 10.4 to 15.9 g/dL), the median decline of the Hb level was 2.9 g/dL (range, 0.3 to 6.3 g/dL); this drop was statistically significant (p < 0.001, 95% confidence interval). Patients who received preoperative blood transfusions (n = 8, 28%) had a significantly increased risk of developing postoperative complications (p = 0.028). Conclusions Preoperative chemotherapy for locally advanced esophagogastric cancer induces anemia and therefore leads to preoperative blood supplementation in a considerable number of patients. Data indicate that this may counteract the beneficial effects of neoadjuvant treatment.
KW - 7
UR - http://www.scopus.com/inward/record.url?scp=4444292758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4444292758&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2004.01.049
DO - 10.1016/j.athoracsur.2004.01.049
M3 - Article
C2 - 15337044
AN - SCOPUS:4444292758
SN - 0003-4975
VL - 78
SP - 1037
EP - 1041
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 3
ER -